Back to Search Start Over

Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease

Authors :
Eloy Rodríguez-Rodríguez
Jordi Pegueroles
Frederic Sampedro
Maria Carmona-Iragui
Didac Vidal-Piñeiro
Ana Pozueta
Juan Fortea
Jordi Clarimón
Rafael Blesa
Daniel Alcolea
Santiago Medrano
Sofía Antón-Aguirre
Alberto Lleó
Estrella Morenas-Rodríguez
MaBelén Sánchez-Saudinós
David Bartrés-Faz
Pascual Sánchez-Juan
Sofía González-Ortiz
Eduard Vilaplana
Victor Montal
Andrea González-Suárez
Isabel Sala
Source :
NEUROBIOLOGY OF AGING, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname
Publication Year :
2015
Publisher :
Elsevier BV, 2015.

Abstract

Cerebrospinal fluid YKL-40 has been described as a marker of glial inflammation. We aimed to study the relationship between YKL-40 and brain structure and its interactions with core Alzheimer's disease (AD) biomarkers. We measured cortical thickness (CTh) and cerebrospinal fluid biomarkers (amyloid-beta 1-42 [A beta 42], total tau, p-tau, and YKL-40) of 80 cognitively normal controls and 27 patients with amnestic mild cognitive impairment. Subjects were classified as A beta 42+ (550 pg/mL). CTh difference maps were derived from the interaction and correlation analyses in the whole sample and within clinical groups. There was a strong correlation between YKL-40 and markers of neurodegeneration (total tau and p-tau). In the whole sample, we found a negative correlation between YKL-40 and CTh in AD vulnerable areas in A beta 42+ subjects but not in A beta 42 participants. Our results suggest that YKL-40 could track the inflammatory processes associated to tau-related neurodegeneration in the presence of the AD pathophysiological process. (C) 2015 Elsevier Inc. All rights reserved.

Details

ISSN :
01974580
Volume :
36
Database :
OpenAIRE
Journal :
Neurobiology of Aging
Accession number :
edsair.doi.dedup.....f5bbcf1684db7f721dc08f7ca0b67bac
Full Text :
https://doi.org/10.1016/j.neurobiolaging.2015.03.001